Most cited papers from Genecast (China)

Genecast (China)

What are the most cited papers from Genecast (China)?

The most cited paper from Genecast (China) is "Local mutational diversity drives intratumoral immune heterogeneity in non-small cell lung cancer" (Qingzhu Jia, Wei Wu, Yuqi Wang et al., 2018), with 549 citations. Next come "Tumor neoantigens: from basic research to clinical applications" (404) and "Tislelizumab combined with chemotherapy as neoadjuvant therapy for surgically resectable esophageal cancer: A prospective, single-arm, phase II study (TD-NICE)" (243).

Published TypeFieldAccessCitations

Showing 50 of 60 papers. Every paper with more than 23 citations is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	Local mutational diversity drives intratumoral immune heterogeneity in non-small cell lung cancer Qingzhu Jia, Wei Wu, Yuqi Wang et al. · Nature Communications Open access	12 Dec 2018	549
2	Tumor neoantigens: from basic research to clinical applications Tao Jiang, Tao Shi, Henghui Zhang et al. · Journal of Hematology & Oncology Open access	6 Sep 2019	404
3	Tislelizumab combined with chemotherapy as neoadjuvant therapy for surgically resectable esophageal cancer: A prospective, single-arm, phase II study (TD-NICE) Xiaolong Yan et al. · International Journal of Surgery	18 May 2022	243
4	Predicting response to immunotherapy in advanced non-small-cell lung cancer using tumor mutational burden radiomic biomarker Bingxi He, Di Dong, Yunlang She et al. · Journal for ImmunoTherapy of Cancer Open access	Jul 2020	191
5	Efficacy and Biomarker Analysis of Camrelizumab in Combination with Apatinib in Patients with Advanced Nonsquamous NSCLC Previously Treated with Chemotherapy Caicun Zhou et al. · Clinical Cancer Research	22 Jan 2021	132
6	PD-L1 expression and tumor mutational burden status for prediction of response to chemotherapy and targeted therapy in non-small cell lung cancer Yanhui Chen, Quanxing Liu, Zhiming Chen et al. · Journal of Experimental & Clinical Cancer Research Open access	14 May 2019	111
7	Genomic landscape and its correlations with tumor mutational burden, PD-L1 expression, and immune cells infiltration in Chinese lung squamous cell carcinoma Tao Jiang, Jinpeng Shi, Zhengwei Dong et al. · Journal of Hematology & Oncology Open access	12 Jul 2019	109
8	Diagnostic value of circulating cell-free DNA levels for hepatocellular carcinoma Linlin Yan, Yanhui Chen, Jiyuan Zhou et al. · International Journal of Infectious Diseases Open access	8 Dec 2017	105
9	The frequency and inter-relationship of PD-L1 expression and tumour mutational burden across multiple types of advanced solid tumours in China Yanhui Chen, Yating Wang, Hongli Luo et al. · Experimental Hematology and Oncology Open access	3 Aug 2020	88
10	Multimodal analysis of cell-free DNA whole-methylome sequencing for cancer detection and localization Fenglong Bie et al. · Nature Communications Open access	27 Sep 2023	87
11	Multiplex immunofluorescence and single‐cell transcriptomic profiling reveal the spatial cell interaction networks in the non‐small cell lung cancer microenvironment Haoxin Peng, Xiangrong Wu, Shaopeng Liu et al. · Clinical and Translational Medicine Open access	2023	86
12	NOTCH3 is a Prognostic Factor and Is Correlated With Immune Tolerance in Gastric Cancer Yuehong Cui, Qian Li, Wei Li et al. · Frontiers in Oncology Open access	5 Jan 2021	80
13	Tracking Neoantigens by Personalized Circulating Tumor DNA Sequencing during Checkpoint Blockade Immunotherapy in Non‐Small Cell Lung Cancer Qingzhu Jia, Lu-Ting Chiu, Shuangxiu Wu et al. · Advanced Science Open access	26 Mar 2020	78
14	Development and Clinical Application of a Rapid and Sensitive Loop-Mediated Isothermal Amplification Test for SARS-CoV-2 Infection Xuejiao Lina Hu, Qianyun Deng, Junmin Li et al. · mSphere Open access	26 Aug 2020	77
15	Massive PD-L1 and CD8 double positive TILs characterize an immunosuppressive microenvironment with high mutational burden in lung cancer Libin Zhang, Yanhui Chen, Han Wang et al. · Journal for ImmunoTherapy of Cancer Open access	Jun 2021	75
16	Paclitaxel liposome for injection (Lipusu) plus cisplatin versus gemcitabine plus cisplatin in the first‐line treatment of locally advanced or metastatic lung squamous cell carcinoma: A multicenter, randomized, open‐label, parallel controlled clinical study Jie Zhang et al. · 癌症：英文版 Open access	26 Oct 2021	69
17	Tumor copy-number alterations predict response to immune-checkpoint-blockade in gastrointestinal cancer Zhihao Lü, Huan Chen, Shuang Li et al. · Journal for ImmunoTherapy of Cancer Open access	Aug 2020	69
18	Profiling Tumor Immune Microenvironment of Non-Small Cell Lung Cancer Using Multiplex Immunofluorescence Haoxin Peng, Xiangrong Wu, Ran Zhong et al. · Frontiers in Immunology Open access	4 Nov 2021	65
19	Mutational Landscape and Evolutionary Pattern of Liver and Brain Metastasis in Lung Adenocarcinoma Tao Jiang, Zhaoyuan Fang, Shijie Tang et al. · Journal of Thoracic Oncology Open access	11 Nov 2020	60
20	Prediction of immune checkpoint inhibition with immune oncology-related gene expression in gastrointestinal cancer using a machine learning classifier Zhihao Lü, Huan Chen, Xi Jiao et al. · Journal for ImmunoTherapy of Cancer Open access	Aug 2020	56
21	On-treatment blood TMB as predictors for camrelizumab plus chemotherapy in advanced lung squamous cell carcinoma: biomarker analysis of a phase III trial Tao Jiang et al. · Molecular Cancer Open access	3 Jan 2022	54
22	A Noninvasive Multianalytical Approach for Lung Cancer Diagnosis of Patients with Pulmonary Nodules Quanxing Liu, Dong Zhou, Tiancheng Han et al. · Advanced Science Open access	7 May 2021	53
23	Immune suppressive microenvironment in brain metastatic non-small cell lung cancer: comprehensive immune microenvironment profiling of brain metastases versus paired primary lung tumors (GASTO 1060) Meichen Li, Xue Hou, Ke Sai et al. · OncoImmunology Open access	31 Mar 2022	52
24	Somatic POLE exonuclease domain mutations elicit enhanced intratumoral immune responses in stage II colorectal cancer Shaobo Mo, Xiaoji Ma, Yaqi Li et al. · Journal for ImmunoTherapy of Cancer Open access	Aug 2020	48
25	PTCH1 mutation promotes antitumor immunity and the response to immune checkpoint inhibitors in colorectal cancer patients Yanni Wang et al. · Cancer Immunology Immunotherapy Open access	24 May 2021	47
26	Molecular profiles and tumor mutational burden analysis in Chinese patients with gynecologic cancers Min Wang, Wensheng Fan, Mingxia Ye et al. · Scientific Reports Open access	6 Jun 2018	46
27	Genomic features and tumor immune microenvironment alteration in NSCLC treated with neoadjuvant PD-1 blockade Shuhang Wang, Pei Yuan, Beibei Mao et al. · npj Precision Oncology Open access	13 Jan 2022	45
28	Targeted Therapy with Anlotinib for a Patient with an Oncogenic FGFR3 - TACC3 Fusion and Recurrent Glioblastoma Yong Wang, Dandan Liang, Jimin Chen et al. · The Oncologist Open access	19 Sep 2020	43
29	DNA Damage Repair Gene Mutations Are Indicative of a Favorable Prognosis in Colorectal Cancer Treated With Immune Checkpoint Inhibitors Yipeng Song, Jian Ping Huang, Dandan Liang et al. · Frontiers in Oncology Open access	19 Feb 2021	41
30	Cell-free DNA copy number variations predict efficacy of immune checkpoint inhibitor-based therapy in hepatobiliary cancers Yang Xu, Ying Hu, Keyan Yang et al. · Journal for ImmunoTherapy of Cancer Open access	May 2021	40
31	Serological biomarkers predict immune-related adverse events and clinical benefit in patients with advanced gastrointestinal cancers Yanni Wang, Jianling Zou, Yun Li et al. · Frontiers in Immunology Open access	8 Sep 2022	39
32	Prognostic Significance of Gene Signature of Tertiary Lymphoid Structures in Patients With Lung Adenocarcinoma Hong Feng, Fujun Yang, Lihong Qiao et al. · Frontiers in Oncology Open access	26 Jul 2021	39
33	Serological Markers Associated With Response to Immune Checkpoint Blockade in Metastatic Gastrointestinal Tract Cancer Zhihao Lü, Jianling Zou, Ying Hu et al. · JAMA Network Open Open access	24 Jul 2019	39
34	A genomic mutation signature predicts the clinical outcomes of immunotherapy and characterizes immunophenotypes in gastrointestinal cancer Xi Jiao, Xin Lan Wei, Shuang Li et al. · npj Precision Oncology Open access	4 May 2021	37
35	Biomarkers of response to camrelizumab combined with apatinib: an analysis from a phase II trial in advanced triple-negative breast cancer patients Jieqiong Liu, Ying Li, Qian Li et al. · Breast Cancer Research and Treatment	25 Feb 2021	37
36	Cellular dynamics in tumour microenvironment along with lung cancer progression underscore spatial and evolutionary heterogeneity of neutrophil Haoxin Peng, Xiangrong Wu, Shaopeng Liu et al. · Clinical and Translational Medicine Open access	Jul 2023	36
37	miR‑454‑3p inhibits non‑small cell lung cancer cell proliferation and metastasis by targeting TGFB2 Hongliang Liao, Yaqin Liang, Lin Kang et al. · Oncology Reports Open access	18 Mar 2021	35
38	Low Infiltration of CD8+ PD-L1+ T Cells and M2 Macrophages Predicts Improved Clinical Outcomes After Immune Checkpoint Inhibitor Therapy in Non-Small Cell Lung Carcinoma Liuning Li, Guojie Lu, Yang Liu et al. · Frontiers in Oncology Open access	4 Jun 2021	34
39	Probe-based association analysis identifies several deletions associated with average daily gain in beef cattle Lingyang Xu, Liu Yang, Lei Wang et al. · BMC Genomics Open access	10 Jan 2019	34
40	PD-1/PD-L1 combined with LAG3 is associated with clinical activity of immune checkpoint inhibitors in metastatic primary pulmonary lymphoepithelioma-like carcinoma Yu-Min Zhong et al. · Frontiers in Immunology Open access	3 Oct 2022	33
41	The mutational pattern of homologous recombination (HR)-associated genes and its relevance to the immunotherapeutic response in gastric cancer Yue Fan, Haifeng Ying, Xueying Wu et al. · Cancer Biology and Medicine Open access	2020	32
42	Peripheral cytokine levels as predictive biomarkers of benefit from immune checkpoint inhibitors in cancer therapy Shoujian Ji, Huan Chen, Keyan Yang et al. · Biomedicine & Pharmacotherapy Open access	2 Jul 2020	32
43	Nivolumab-associated DRESS in a genetic susceptible individual Luoyan Ai, Jie Gao, Shihai Zhao et al. · Journal for ImmunoTherapy of Cancer Open access	Oct 2021	31
44	Heterogeneity of neoantigen landscape between primary lesions and their matched metastases in lung cancer Tao Jiang, Ruirui Cheng, Yuanwei Pan et al. · Translational Lung Cancer Research Open access	Apr 2020	31
45	Tertiary Lymphoid Structures Gene Signature Predicts Prognosis and Immune Infiltration Analysis in Head and Neck Squamous Cell Carcinoma Ai‐Yan Xing, Dongxiao Lv, Changshun Wu et al. · Current Genomics Open access	29 Jan 2024	30
46	EGFR Mutation and 11q13 Amplification Are Potential Predictive Biomarkers for Immunotherapy in Head and Neck Squamous Cell Carcinoma Shengjin Dou, Lin Zhang, Chong Wang et al. · Frontiers in Immunology Open access	16 Mar 2022	29
47	The CD68+ macrophages to CD8+ T-cell ratio is associated with clinical outcomes in hepatitis B virus (HBV)-related hepatocellular carcinoma Haibei Xin et al. · HPB Open access	11 Dec 2020	29
48	The mutational pattern of homologous recombination-related (HRR) genes in Chinese colon cancer and its relevance to immunotherapy responses Pei Fu Zhou, Xueying Wu, Huan Chen et al. · Aging Open access	9 Dec 2020	29
49	Mutational Landscape of cfDNA Identifies Distinct Molecular Features Associated With Therapeutic Response to First-Line Platinum-Based Doublet Chemotherapy in Patients with Advanced NSCLC Tao Jiang et al. · Theranostics Open access	2017	29
50	Spatial interactions of immune cells as potential predictors to efficacy of toripalimab plus chemotherapy in locally advanced or metastatic pancreatic ductal adenocarcinoma: a phase Ib/II trial Ke Cheng et al. · Signal Transduction and Targeted Therapy Open access	25 Nov 2024	28

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.